The Daily Papule

J Derm Treat

Patients' and clinicians' perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study.

Henckens NFT, Pawlak ME, Wanten SAC, Weng YC, V Ee I, Arents BWM, Witkamp L, de Bruin-Weller MS, Baerveldt EM, Seyger MMB, de Jong EMGJ, van Enst WA, van den Reek JMPA

Journal of Dermatological TreatmentIn the feed 10 Aug 2026, published online 10 Aug 2026, issue 2026 Dec, added to PubMed 10 Aug 2026

Topics: PsoriasisAtopic dermatitis & eczemaPractice, education & research

Abstract

BACKGROUNDFor patients with stable psoriasis or atopic dermatitis (AD) receiving systemic treatment, telemedicine may offer a viable alternative to in-person consultations. However, perspectives of these patients and dermatological care providers (DCPs) regarding telemedicine are underexplored, yet essential for successful implementation.

OBJECTIVESTo explore experiences, preferences, and perspectives of patients and DCPs regarding telemedicine for patients with psoriasis or AD on systemic treatment.

METHODSA mixed-methods study was conducted using surveys and semi-structured interviews with patients and DCPs.

RESULTSSurveys were completed by 162 patients and 152 DCPs, and interviews by 12 patients and 5 DCPs. Both groups expressed positive attitudes toward telemedicine, provided stable disease. Patients valued telemedicine for practical benefits, including time/cost savings, but emphasized the importance of an established relationship with DCPs before its initiation. DCPs identified key enablers including improved ICT-support, user-friendly systems, and adequate reimbursement. The majority of patients and DCPs supported telemedicine implementation, with telephonic consultations as preferred method. Many DCPs believed ≥50% of consultations could be conducted through telemedicine. Additionally, telemedicine leads to substantial CO2-equivalent emission reduction.

CONCLUSIONPatients and DCPs supported further implementation of telemedicine in patients with stable psoriasis or AD on systemic treatment and identified practical, financial and societal facilitators.

Abstract from PubMed

PMID 42573065 · DOI 10.1080/09546634.2026.2703354